Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alto Neuroscience, Inc. (ANRO)
NYSE:ANRO
RESEARCH TOOLSreports
Alto Neuroscience, Inc. (ANRO) Stock Price & Analysis
42 Followers
ANRO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.40 - $24.00
Previous Close$14.99
Volume79.86K
Average Volume (3M)127.21K
Market Cap
$402.99M
Enterprise Value$330.30M
Total Cash (Recent Filing)$82.55M
Total Debt (Recent Filing)$9.86M
Price to Earnings (P/E)―
Beta0.69
Next Earnings
May 14, 2024EPS Estimate
-$0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding26,883,990
10 Day Avg. Volume100,788
30 Day Avg. Volume127,208
Standard Deviation0.13
R-Squared0.47
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)-1.39
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$37.50Price Target Upside150.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Alto Neuroscience, Inc. News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsSuccess in either Phase 2b program can drive substantial upside to the valuation, given MDD remains a major societal problem impacting millions of patients.
Financial StabilityCompany has a cash runway into 2027, indicating strong financial stability.
Sales ProjectionsAnalyst projects blockbuster sales with peak U.S. sales of $1.6Bn and $1.7Bn for ALTO-100 and ALTO-300 respectively by 2035 and 2036.
Bears Say
EarningsManagement reported EPS of ($0.76) for 1Q24, compared to estimates of ($0.47)/($0.46), driven by increased operating expenses related to the two Phase 2b trials.
Financial PerformanceANRO reported a net loss of $13.4MM.
Financial PerformanceANRO reported a net loss of $36.3MM, which reflects the company's current stage of development and investment in research and development.
---
Ownership Overview
25.03% Insiders
10.60% Mutual Funds
3.57% Other Institutional Investors
60.80% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ANRO FAQ
What was Alto Neuroscience, Inc.’s price range in the past 12 months?
Alto Neuroscience, Inc. lowest stock price was $9.40 and its highest was $24.00 in the past 12 months.
What is Alto Neuroscience, Inc.’s market cap?
Currently, no data Available
When is Alto Neuroscience, Inc.’s upcoming earnings report date?
Alto Neuroscience, Inc.’s upcoming earnings report date is May 14, 2024 which is 69 days ago.
How were Alto Neuroscience, Inc.’s earnings last quarter?
Alto Neuroscience, Inc. released its earnings results on Mar 21, 2024. The company reported -$2.8 earnings per share for the quarter, missing the consensus estimate of -$0.835 by -$1.965.
Is Alto Neuroscience, Inc. overvalued?
According to Wall Street analysts Alto Neuroscience, Inc.’s price is currently Undervalued.
Does Alto Neuroscience, Inc. pay dividends?
Alto Neuroscience, Inc. does not currently pay dividends.
What is Alto Neuroscience, Inc.’s EPS estimate?
Alto Neuroscience, Inc.’s EPS estimate is -$0.46.
How many shares outstanding does Alto Neuroscience, Inc. have?
Alto Neuroscience, Inc. has 26,883,990 shares outstanding.
What happened to Alto Neuroscience, Inc.’s price movement after its last earnings report?
Alto Neuroscience, Inc. reported an EPS of -$2.8 in its last earnings report, missing expectations of -$0.835. Following the earnings report the stock price went down -2.26%.
Which hedge fund is a major shareholder of Alto Neuroscience, Inc.?
Among the largest hedge funds holding Alto Neuroscience, Inc.’s share is RA Capital Management. It holds Alto Neuroscience, Inc.’s shares valued at 21M.
---
Alto Neuroscience, Inc. Stock Smart Score
Company Description
Alto Neuroscience, Inc.
Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine neuropsychiatric care by leveraging neurobiology to develop personalized and highly effective treatment options. Through our AI-enabled biomarker platform, we combine rich sources of information on patients¿ brain activity and behavior to better identify which patients are more likely to respond to our novel product candidates.
---
ANRO Stock 12 Month Forecast
Average Price Target
$37.50
▲(150.17% Upside)
Technical Analysis
Best Analysts Covering ANRO
1 Year
1 Year Success Rate
3/3 ratings generated profit
1 Year Average Return
+15.20%
initiated a buy rating last month
Copying Brian Skorney's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +15.20% per trade.
---